Acadia Pharmaceuticals is pleased to share that Health Canada has accepted their New Drug Submission (NDS) of trofinetide for the treatment of Rett Syndrome. Moreover, the treatment has been granted Priority Review to help expedite review timelines.

As you already know, Canadians living with Rett Syndrome, and their caregivers, lack options to treat the array of debilitating symptoms associated with this rare, neurodevelopment disorder. Should trofinetide receive Health Canada approval, it will be the first and only Rett Syndrome treatment in Canada – a pivotal and hopeful milestone for Canadians impacted by the disease.

Acadia Pharmaceuticals is committed to leading neuroscience breakthroughs and advancing treatment options for those living with rare diseases. We are excited to bring this commitment to Canada to improve the understanding of rare diseases and find solutions for life-altering conditions, like Rett Syndrome, through research, treatment innovation, and patient support programs.